<DOC>
	<DOC>NCT01008852</DOC>
	<brief_summary>This study is designed to evaluate the safety and efficacy of a dose and dosage regimen of SBI-087 in seropositive patients with active Rheumatoid Arthritis, who are on a stable dose of methotrexate.</brief_summary>
	<brief_title>Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Meets the American College of Rheumatology (ACR) 1987 revised criteria for classification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening Active RA as defined by &gt;= 5 swollen and &gt;= 5 tender joints (28joint count) and at least 1 of the following: Creactive protein &gt;= 10 mg/L or Erythrocyte Sedimentation Rate &gt;= 28 mm/h Must be seropositive as defined by a documented history of rheumatoid factor (RF) or anticyclic citrullinated peptide (antiCCP) positivity Must be receiving a stable route and dose of methotrexate (up to 25 mg weekly) Any significant health problem other than rheumatoid arthritis Any clinically significant laboratory abnormalities Any prior use of B celldepleting therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>seropositive</keyword>
	<keyword>methotrexate</keyword>
</DOC>